Diagnostics Pipeline: 2024 Trends in FDA Approvals
In vitro diagnostic products approved by the U.S. Food and Drug Administration in 2024 show a continued move toward rapid and point-of-care tests
Keeps You Up-to-Date on New Diagnostic Tests, Testing Trends and Opportunities, and Emerging Test Technologies
In vitro diagnostic products approved by the U.S. Food and Drug Administration in 2024 show a continued move toward rapid and point-of-care tests
From - Diagnostic Testing & Emerging Technologies
Clinically relevant pharmacogenomic findings are seen in single nucleotide polymorphism (SNP) genotyping and exome sequencing data…
From - Diagnostic Testing & Emerging Technologies
Reference pricing is associated with nearly a one-third reduction in the average price paid for 285 different types of tests, according to a…
From - Diagnostic Testing & Emerging Technologies
Health care corporate venture capital (CVC) is increasing across all sectors of the industry in terms of number of deals, dollars invested, and number of…
From - Diagnostic Testing & Emerging Technologies
The United States has the screening capacity to meet colorectal screening goals, but this capacity has so far not translated into increased screening rates, according to a…